Bitterman Kevin 4

Accession 0001104659-25-121740

CIK 0001816736other

View on SEC.gov Company Profile

Filed

Dec 15, 7:00 PM ET

Accepted

Dec 16, 9:43 PM ET

Size

42.2 KB

Accession

0001104659-25-121740

Insider Transaction Report

Form 4

Period: 2025-12-12

Disc Medicine, Inc.IRON

Bitterman Kevin

Director

Transactions

Sale
Common Stock
2025-12-12$92.05/sh−16,403$1,509,896→ 425,633 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$92.58/sh−3,852$356,618→ 421,781 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$93.80/sh−3,446$323,235→ 418,335 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$92.05/sh−8,527$784,910→ 377,022 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$92.58/sh−2,005$185,623→ 375,017 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$93.80/sh−1,793$168,183→ 373,224 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$92.05/sh−6,570$604,769→ 44,430 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$92.58/sh−1,540$142,573→ 42,890 total(indirect: See footnote)
Sale
Common Stock
2025-12-12$93.80/sh−1,371$128,600→ 41,519 total(indirect: See footnote)
Sale
Common Stock
2025-12-15$91.18/sh−28,913$2,636,287→ 389,422 total(indirect: See footnote)
Sale
Common Stock
2025-12-15$92.01/sh−3,921$360,771→ 385,501 total(indirect: See footnote)
Sale
Common Stock
2025-12-15$91.18/sh−14,811$1,350,467→ 358,413 total(indirect: See footnote)
Sale
Common Stock
2025-12-15$92.01/sh−2,049$188,528→ 356,364 total(indirect: See footnote)
Sale
Common Stock
2025-12-15$91.18/sh−11,427$1,041,914→ 30,092 total(indirect: See footnote)
Sale
Common Stock
2025-12-15$92.01/sh−1,572$144,640→ 28,520 total(indirect: See footnote)
Exercise/Conversion
Common Stock
2025-12-15$13.50/sh+7,000$94,500→ 7,000 total
Sale
Common Stock
2025-12-15$91.87/sh−7,000$643,090→ 0 total
Sale
Common Stock
2025-12-16$91.24/sh−35,898$3,275,334→ 349,603 total(indirect: See footnote)
Sale
Common Stock
2025-12-16$91.24/sh−18,666$1,703,086→ 337,698 total(indirect: See footnote)
Sale
Common Stock
2025-12-16$91.24/sh−14,359$1,310,115→ 14,161 total(indirect: See footnote)
Exercise/Conversion
Stock Option (Right to Buy)
2025-12-15−7,000→ 0 total
Exercise: $13.50Exp: 2032-12-28→ Common Stock (7,000 underlying)

Footnotes (11)

[F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.5289 to $92.4325 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3), (4), (7), (8), (9) and (10).
[F10]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.705 inclusive.
[F11]Fully Vested.
[F2]These shares are held by Atlas Venture Opportunity Fund I, LP ("Opportunity I"). The general partner of Opportunity I is Atlas Venture Associates Opportunity I, LP ("Associates I"). Atlas Venture Associates Opportunity I, LLC ("Associates I LLC") is the general partner of Associates I. The Reporting Person is a member of Associates I LLC and disclaims beneficial ownership of such securities held by Opportunity I, except to the extent of his pecuniary interest therein, if any.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.3796 inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.52 to $94.255 inclusive.
[F5]These shares are held by Atlas Venture Opportunity Fund II, LP ("Opportunity II"). The general partner of Opportunity II is Atlas Venture Associates Opportunity II, LP ("Associates II"). Atlas Venture Associates Opportunity II, LLC ("Associates II LLC") is the general partner of Associates II. The Reporting Person is a member of Associates II LLC and disclaims beneficial ownership of such securities held by Opportunity II, except to the extent of his pecuniary interest therein, if any.
[F6]These shares are held by Atlas Venture Fund XII, L.P. ("Atlas XII"). The general partner of Atlas XII is Atlas Venture Associates XII, L.P. ("Associates XII"). Atlas Venture Associates XII, LLC ("Associates XII LLC") is the general partner of Associates XII. The Reporting Person is a member of Associates XII LLC and disclaims beneficial ownership of such securities held by Atlas XII, except to the extent of his pecuniary interest therein, if any.
[F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.00 to $91.99 inclusive.
[F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.48 inclusive.
[F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.79 to $91.95 inclusive.

Documents

1 file

4
tm2530644-8_4seq1.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Disc Medicine, Inc.

CIK 0001816736

→

Entity typeother

Related Parties

filerCIK 0001591747

Filing Metadata

Form type: 4
Filed: Dec 15, 7:00 PM ET
Accepted: Dec 16, 9:43 PM ET
Size: 42.2 KB

View on SEC.gov